Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,551
  • Shares Outstanding, K 265,052
  • Annual Sales, $ 178,030 K
  • Annual Income, $ -70,810 K
  • EBIT $ -154 M
  • EBITDA $ -143 M
  • 60-Month Beta 2.49
  • Price/Sales 0.10
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.62
  • Most Recent Earnings $-0.11 on 08/13/25
  • Next Earnings Date 11/12/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.12
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0417 +31.65%
on 10/21/25
0.2750 -80.04%
on 10/09/25
-0.0921 (-62.65%)
since 09/26/25
3-Month
0.0403 +36.23%
on 09/08/25
0.2750 -80.04%
on 10/09/25
-0.2920 (-84.17%)
since 07/25/25
52-Week
0.0403 +36.23%
on 09/08/25
0.8600 -93.62%
on 11/06/24
-0.6826 (-92.56%)
since 10/25/24

Most Recent Stories

More News
Adaptimmune Announces Delisting from Nasdaq

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's...

ADAP : 0.0549 (-15.15%)
Adaptimmune Reports Q2 Financial Results and Provides Business Update

Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US...

ADAP : 0.0549 (-15.15%)
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price...

ADAP : 0.0549 (-15.15%)
Adaptimmune Reports Q1 Financial Results and Provides Business Update

TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel...

ADAP : 0.0549 (-15.15%)
Adaptimmune Provides Q4 and Full Year 2024 Business Update

TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission...

ADAP : 0.0549 (-15.15%)
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 0.0549 (-15.15%)
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers...

ADAP : 0.0549 (-15.15%)
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assetsAdaptimmune Allo-T program to be featured...

ADAP : 0.0549 (-15.15%)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from the...

ADAP : 0.0549 (-15.15%)
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcomaPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December...

ADAP : 0.0549 (-15.15%)

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 0.0833
2nd Resistance Point 0.0767
1st Resistance Point 0.0658
Last Price 0.0549
1st Support Level 0.0483
2nd Support Level 0.0417
3rd Support Level 0.0308

See More

52-Week High 0.8600
Fibonacci 61.8% 0.5469
Fibonacci 50% 0.4502
Fibonacci 38.2% 0.3534
Last Price 0.0549
52-Week Low 0.0403

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar